Literature DB >> 26794859

Spondyloarthropathies: IL-17A blockade ameliorates ankylosing spondylitis.

João H Duarte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26794859     DOI： 10.1038/nrrheum.2016.7

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Authors:  Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245
  1 in total
  8 in total

Review 1.  Secukinumab: A New Treatment Option for Psoriatic Arthritis.

Authors:  Philip Mease; Iain B McInnes
Journal:  Rheumatol Ther       Date:  2016-04-23

2.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors:  Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Drug Discov       Date:  2017-12-28       Impact factor: 84.694

3.  Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center.

Authors:  Eleftherios Pelechas; Evripidis Kaltsonoudis; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2019-03-15       Impact factor: 2.631

4.  Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis.

Authors:  Berkan Armağan; Levent Kılıç; Bayram Farisoğulları; Gözde Kübra Yardımcı; Emre Bilgin; Ertuğrul Çağrı Bölek; Ömer Karadağ; Şule Apraş Bilgen; Sedat Kiraz; İhsan Ertenli; Umut Kalyoncu
Journal:  Rheumatol Int       Date:  2022-09-21       Impact factor: 3.580

5.  Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.

Authors:  Karel Pavelka; Alan Kivitz; Eva Dokoupilova; Ricardo Blanco; Marco Maradiaga; Hasan Tahir; Luminita Pricop; Mats Andersson; Aimee Readie; Brian Porter
Journal:  Arthritis Res Ther       Date:  2017-12-22       Impact factor: 5.156

6.  Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.

Authors:  H Marzo-Ortega; J Sieper; A Kivitz; R Blanco; M Cohen; R Martin; A Readie; H B Richards; B Porter
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-06-07       Impact factor: 4.794

7.  Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

Authors:  Helena Marzo-Ortega; Joachim Sieper; Alan Kivitz; Ricardo Blanco; Martin Cohen; Evie-Maria Delicha; Susanne Rohrer; Hanno Richards
Journal:  RMD Open       Date:  2017-12-28

8.  Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.

Authors:  J Braun; H Haibel; M de Hooge; R Landewé; M Rudwaleit; T Fox; A Readie; H B Richards; B Porter; R Martin; D Poddubnyy; J Sieper; D van der Heijde
Journal:  Arthritis Res Ther       Date:  2019-06-07       Impact factor: 5.156
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.